Beginnings of Personalized Medicine for Myeloma

Ajai Chari, MD

Video Categories: Personalized Medicine

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
June 16, 2015

The Biomarker: Melanoma

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.

October 10, 2016

Immunotherapy’s Role in Treating Hormone Receptor–Positive Diseases

Dr Thomas Bachelot discusses the potential for incorporating immunotherapy into the treatment of patients with hormone receptor–positive diseases but notes that the current data are weak, and further studies are needed to get a better sense of the viability of this treatment option.